Trump Administration Considers Rescheduling Marijuana: Risks and Benefits

Potential Rescheduling of Marijuana

• 🎯 The Trump administration is reportedly considering reclassifying marijuana from a Schedule I drug to a Schedule III drug.
• 💡 Currently, Schedule I includes drugs like heroin and LSD, while Schedule III includes substances like ketamine and Tylenol with codeine.
• 📈 Supporters argue this change would facilitate medical research on cannabis.

Concerns Over Increased Potency and Harm

• ⚠️ Critics, like Kevin Sabbat of Smarter Smart Approaches to Marijuana, argue that modern marijuana is significantly more potent than in the past due to genetic modification.
• 🧠 High-potency cannabis is linked to increased risks of psychosis, schizophrenia, learning disabilities, and other psychological and physical problems, including heart disease and diabetes.
• 🚫 Sabbat suggests that if cannabis has medical benefits, it should be researched and distributed through the FDA and pharmacies, similar to prescription drugs.

Impact on Public Perception and Commercialization

• 📉 Reclassifying marijuana could send a message that it is less dangerous, potentially influencing younger people, despite its increased potency.
• 💰 The move could also provide tax breaks to the cannabis industry, leading to increased advertising and full commercialization, drawing parallels to the negative outcomes of the tobacco industry.

Addiction and Public Use Issues

• 📈 A recent report indicates that nearly 30% of patients using marijuana for medical purposes are addicted, with a higher daily use rate compared to alcohol.
• 💨 Concerns are rising about public use of marijuana, with people unable to avoid secondhand smoke, and a push for businesses to allow cannabis consumption, even as cigarette smoking is restricted in public spaces.
• ⚖️ There is a growing sentiment that states are moving too quickly towards public use without fully understanding the consequences.